Updated results from ASCENT-J02, a study of sacituzumab govitecan in Japanese participants with metastatic triple-negative breast cancer
Abstract Background Sacituzumab govitecan (SG) is approved in Japan for pretreated unresectable or recurrent triple-negative breast cancer (TNBC). ASCENT-J02 is an open-label, phase 1/2 study of SG in Japanese patients. At primary analysis (median follow-up, 6.1 months) of the metastatic TNBC (mTNBC) cohort ( n = 36), objective response rate (ORR) was 25.0% (95% CI: 12.1–42.2; P = 0.0077), median progression-free survival (PFS) was 5.6 months (95% CI: 3.9–not reached), and SG had a manageable safety profile, consistent with the global phase 3 ASCENT study. We report updated outcomes, including the first overall survival (OS) results. Methods Patients with pretreated mTNBC received 10 mg/kg SG intravenously on days 1 and 8 of 21-day cycles. The primary endpoint was independent review committee-assessed ORR (RECIST v1.1). Secondary endpoints included PFS, duration of response, time to response, OS, and safety. Results With median follow-up of 15.9 months for 36 patients with mTNBC, ORR with SG was 31% (95% CI: 16–48); four complete responses were observed. Median PFS was 5.6 months (95% CI: 3.9–15.8), and median OS was 15.9 months (95% CI: 10.4–22.4). No treatment-emergent adverse events (TEAEs) led to treatment discontinuation or death. Grade ≥ 3 TEAEs were observed in 26 (72%) patients; most frequent were neutropenia (58%), leukopenia (36%), and diarrhea (11%). Conclusions With longer follow-up, SG continued to demonstrate efficacy and safety consistent with the global ASCENT study. These results further support the use of SG in Japanese patients with pretreated mTNBC.
Authors
- Akihiko Shimomura (ORCID: https://orcid.org/0000-0002-2557-8170)
- Yuki Iwahori
- Nobuko Kawaguchi‐Sakita (ORCID: https://orcid.org/0000-0001-8667-1427)
- J. Shao
- Yoichi Naito (ORCID: https://orcid.org/0000-0002-8490-9064)
- Takahiro Kogawa (ORCID: https://orcid.org/0000-0003-3730-6591)
- Norikazu Masuda (ORCID: https://orcid.org/0000-0002-7302-0278)
- Catherine Lai (ORCID: https://orcid.org/0009-0002-6364-5431)
- T. Nakayama (ORCID: https://orcid.org/0000-0002-4023-4560)
- Dianna Gary
- Danh Huynh
- Hiroji Iwata
- Kazuki Sudo
- Koji Matsumoto
- Yutaka Yamamoto
- Takanori Ishida
Institutions
- Nagoya City University (JP)
- Tohoku University Hospital (JP)
- National Center for Global Health and Medicine (JP)
- Kumamoto University Hospital (JP)
- The Cancer Institute Hospital (JP)
- Gilead Sciences (United States) (US)
- National Cancer Center Hospital East (JP)
- Kyoto University Hospital (JP)
- Osaka International Cancer Institute (JP)
- Hyogo Prefectural Cancer Center (JP)
- Japanese Foundation For Cancer Research (JP)
- Gilead Sciences (Japan) (JP)
- National Cancer Center Hospital (JP)
- Nagoya University (JP)
Publication Details
- Journal
- International Journal of Clinical Oncology
- Published
- 2026-11-14
- DOI
- https://doi.org/10.1007/s10147-026-03214-9
- Primary Topic
- Breast Cancer Treatment Studies
- Type
- article
- Field-Weighted Citation Impact
- 0.00